Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Epidemiology (1)
- Epidemiology (2)
- Potential roles of genomics
- Areas for improvement
- Classical prognostic factors
- Example of the adjuvant online software (1)
- Example of the adjuvant online software (2)
- Techniques used in translational studies
- Microarrays
- Representation of microarrays
- RT-PCR
- Example for PCR representation
- Breast cancer biology
- Breast cancer development
- Breast cancer development as seen in microarrays
- Metastatic potential present in early tumor stages
- Gene expression phenotypes in ER+ and ER-
- Grade 1 and grade 3 of tumor differentiation
- Grade 2 tumors
- Molecular taxonomy of breast cancer
- Molecular subtypes and prognosis
- Well defined molecular subtypes
- Luminal vs. basal-like tumors (1)
- Luminal vs. basal-like tumors (2)
- Correlation of subtypes with prognostic profiles
- Prediction of response
- Benefits of predicting response
- Current predictive markers
- Single molecular predictors
- Prediction of response docetaxel - 92 genes
- Prediction of response docetaxel - 85 genes
- Prediction of response paclitaxel
- Prediction of response tamoxifen - 81 genes (1)
- Prediction of response tamoxifen - 81 genes (2)
- Subtypes and response to chemotherapy
- Prognosis
- Importance pf prognosis
- Development of gene predictors
- Amsterdam 70-gene profile (1)
- Amsterdam 70-gene profile (2)
- MammaPrint: independent validation
- Rotterdam 76-gene profile
- Recurrence score 21 gene profile
- Recurrence score by group
- Recurrence score survival
- Recurrence score as a continuous predictor
- Recurrence score independent of size/age
- Development of recurrence score
- Validation of recurrence score (1)
- Validation of recurrence score (2)
- Conditions to use gene profiles
- EORTC-BIG: MINDACT
- TAILOR-x
- Conclusions (1)
- Conclusions (2)
- Acknowledgements
Topics Covered
- DNA microarrays and PCR can provide information about the biology of breast cancer, prediction of response and prognosis
- A molecular taxonomy of breast cancer has been proposed based on gene profiling
- Prediction of response is still inaccurate and further studies should be performed
- Several prognostic profiles have proved advantage over classical prognostic factors
- They could be used in the near future to select patients for adjuvant chemotherapy in breast cancer
Talk Citation
Espinosa, E. (2009, January 6). Gene profiling in breast cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/ZRVM6018.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Enrique Espinosa has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.